

# Wondfo Receives Health Canada Authorization for Distribution of the SAFElife™ Fentanyl Urine Home Test

## *Rapid and sensitive At-Home screening for Fentanyl in urine specimens*

Wondfo, a wholly owned subsidiary of Wondfo Biotech, is pleased to announce that Health Canada has granted authorization for Canadian distribution of the SAFElife™ Fentanyl Urine Home Test, in an extension of our Canadian drug testing portfolio.

The test is designed for rapid, over-the-counter (home) use, for detection of fentanyl at a cutoff of 1ng/mL and, is available in Dip Card or Cassette format.

Fentanyl is 50 times more potent than heroin and 100 times more potent than morphine, posing a significant threat of harm to individuals who ingest it knowingly or unknowingly - alone or in combination with other drugs. 2mg of fentanyl which is 10 times less than the weight of a single grain of rice is considered a lethal dose to an average adult.

"The extension of our SAFElife™ portfolio to include a home test for fentanyl is part of our ongoing commitment to provide innovative solutions to support the fight against the fentanyl epidemic."

— *Wingly Zhan, Senior Manager - Wondfo CA*

Wondfo is a leading international manufacturer of point-of-care tests, providing rapid diagnostic and chronic disease management solutions in four major categories including Toxicology Testing, Infectious Disease, Women's Reproductive Health, and Veterinary Diagnostics. Wondfo operates a substantive Canadian distribution center as well as boasting North American manufacturing and R&D facilities. This commitment to local manufacturing and distribution enhances Wondfo's ability to readily and reliably supply products to the Canadian market.

To learn more about the SAFElife™ Fentanyl Urine Home Test please visit **wondfousa.com**.

Media Contact:

Brian Drake

Vice President, Sales and Downstream Marketing

brian.d@wondfousa.com



bringing science to life

Wondfo USA Co., Ltd.

info@wondfocanada.com

+1 (630) 468-2199 || WondfoUSA.com